Viveve Medical Stock Price, News & Analysis (NASDAQ:VIVE)

$4.98 0.17 (3.53 %)
(As of 11/18/2017 04:00 PM ET)
Previous Close$4.98
Today's Range$4.89 - $5.06
52-Week Range$3.75 - $11.16
Volume119,334 shs
Average Volume207,387 shs
Market Capitalization$96.74 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.59

About Viveve Medical (NASDAQ:VIVE)

Viveve Medical logoViveve Medical, Inc. designs, develops, manufactures and markets a medical device, Geneveve, for the non-invasive treatment of vaginal laxity, for improved sexual function, and for vaginal rejuvenation. The Company's, Geneveve, is a non-invasive solution for vaginal laxity, which includes three components: the Viveve System (a radio frequency (RF), generator housed in a table-top console), a reusable handpiece and a single-use treatment tip, as well as several other consumable accessories. Physicians attach the single-use treatment tip to the handpiece, which is connected to the console. The generator authenticates the treatment tip and programs the system for the desired treatment without further physician intervention. The treatment is performed in a physician's office, in less than 30 minutes, and does not require the use of anesthesia. Geneveve is indicated for use in general surgical procedures for electrocoagulation and hemostasis in the United States.


Industry, Sector and Symbol:
  • Industry: Advanced Medical Equipment & Technology
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:VIVE
  • Previous Symbol: OTCMKTS:PLCSD
  • CUSIP: N/A
  • Web: www.viveve.com
Debt:
  • Debt-to-Equity Ratio: 2.72%
  • Current Ratio: 3.89%
  • Quick Ratio: 3.63%
Sales & Book Value:
  • Annual Sales: $7.14 million
  • Price / Sales: 13.55
  • Book Value: ($0.04) per share
  • Price / Book: -124.50
Profitability:
  • Trailing EPS: ($2.16)
  • Net Income: ($20,110,000.00)
  • Net Margins: -257.58%
  • Return on Equity: -275.77%
  • Return on Assets: -102.12%
Misc:
  • Employees: 42
  • Outstanding Shares: 19,430,000
 

Frequently Asked Questions for Viveve Medical (NASDAQ:VIVE)

What is Viveve Medical's stock symbol?

Viveve Medical trades on the NASDAQ under the ticker symbol "VIVE."

How were Viveve Medical's earnings last quarter?

Viveve Medical, Inc. (NASDAQ:VIVE) announced its earnings results on Wednesday, November, 8th. The company reported ($0.50) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.42) by $0.08. The firm had revenue of $4.07 million for the quarter, compared to the consensus estimate of $4.10 million. Viveve Medical had a negative net margin of 257.58% and a negative return on equity of 275.77%. The company's quarterly revenue was up 120.1% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.46) EPS. View Viveve Medical's Earnings History.

Where is Viveve Medical's stock going? Where will Viveve Medical's stock price be in 2017?

5 brokers have issued 1-year target prices for Viveve Medical's stock. Their forecasts range from $10.00 to $11.00. On average, they expect Viveve Medical's stock price to reach $10.40 in the next twelve months. View Analyst Ratings for Viveve Medical.

Who are some of Viveve Medical's key competitors?

Who are Viveve Medical's key executives?

Viveve Medical's management team includes the folowing people:

  • James G. Atkinson, Chief Business Officer and President (Age 59)
  • Patricia K. Scheller, Chief Executive Officer, Director (Age 57)
  • Scott C. Durbin, Chief Financial Officer (Age 48)
  • Lori H. Bush, Independent Director (Age 60)
  • Daniel S. Janney, Lead Independent Director (Age 51)
  • Debora A. Jorn, Independent Director (Age 59)
  • Arlene M. Morris, Independent Director (Age 65)
  • Jon M. Plexico, Independent Director (Age 49)

When did Viveve Medical IPO?

(vive) raised $13 million in an initial public offering (IPO) on Tuesday, June 14th 2016. The company issued 1,600,000 shares at a price of $8.00 per share. Ladenburg Thalmann and Craig-Hallum Capital Group acted as the underwriters for the IPO and Maxim Group was co-manager.

Who owns Viveve Medical stock?

Viveve Medical's stock is owned by many different of institutional and retail investors. Top institutional investors include RTW Investments LP (7.58%), Perceptive Advisors LLC (2.51%), ING Groep NV (1.67%), Granahan Investment Management Inc. MA (0.53%) and Neuberger Berman Group LLC (0.41%). Company insiders that own Viveve Medical stock include James G Atkinson, Patricia Scheller, Scott Durbin and Stonepine Capital Management,. View Institutional Ownership Trends for Viveve Medical.

Who sold Viveve Medical stock? Who is selling Viveve Medical stock?

Viveve Medical's stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC. View Insider Buying and Selling for Viveve Medical.

Who bought Viveve Medical stock? Who is buying Viveve Medical stock?

Viveve Medical's stock was bought by a variety of institutional investors in the last quarter, including RTW Investments LP, ING Groep NV, Neuberger Berman Group LLC and Granahan Investment Management Inc. MA. Company insiders that have bought Viveve Medical stock in the last two years include James G Atkinson, Patricia Scheller, Scott Durbin and Stonepine Capital Management,. View Insider Buying and Selling for Viveve Medical.

How do I buy Viveve Medical stock?

Shares of Viveve Medical can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viveve Medical's stock price today?

One share of Viveve Medical stock can currently be purchased for approximately $4.98.

How big of a company is Viveve Medical?

Viveve Medical has a market capitalization of $96.74 million and generates $7.14 million in revenue each year. The company earns ($20,110,000.00) in net income (profit) each year or ($2.16) on an earnings per share basis. Viveve Medical employs 42 workers across the globe.

How can I contact Viveve Medical?

Viveve Medical's mailing address is 345 INVERNESS DRIVE SOUTH BUILDING B SUITE 250, ENGLEWOOD CO, 80112. The company can be reached via phone at 720-696-8100 or via email at [email protected]


MarketBeat Community Rating for Viveve Medical (NASDAQ VIVE)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  76 (Vote Outperform)
Underperform Votes:  37 (Vote Underperform)
Total Votes:  113
MarketBeat's community ratings are surveys of what our community members think about Viveve Medical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Viveve Medical (NASDAQ:VIVE)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 0 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $10.40 (108.84% upside)

Consensus Price Target History for Viveve Medical (NASDAQ:VIVE)

Price Target History for Viveve Medical (NASDAQ:VIVE)

Analysts' Ratings History for Viveve Medical (NASDAQ:VIVE)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/16/2017MizuhoInitiated CoverageBuy -> Buy$10.00N/AView Rating Details
10/23/2017Cowen and CompanySet Price TargetBuy$11.00N/AView Rating Details
8/11/2017Maxim GroupReiterated RatingBuy$11.00HighView Rating Details
5/25/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$10.00MediumView Rating Details
5/17/2017B. RileyReiterated RatingBuy$10.00MediumView Rating Details
9/20/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$22.00N/AView Rating Details
(Data available from 11/19/2015 forward)

Earnings

Earnings History and Estimates Chart for Viveve Medical (NASDAQ:VIVE)

Earnings by Quarter for Viveve Medical (NASDAQ:VIVE)

Earnings History by Quarter for Viveve Medical (NASDAQ VIVE)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017Q3 2017($0.42)($0.50)$4.10 million$4.07 millionViewN/AView Earnings Details
8/10/2017Q2 2017($0.33)($0.54)$3.24 million$3.08 millionViewN/AView Earnings Details
5/11/2017Q1 2017($0.51)($0.57)$2.70 million$3.04 millionViewN/AView Earnings Details
11/10/2016Q316($0.48)($0.46)$1.70 million$1.85 millionViewN/AView Earnings Details
8/11/2016Q216($0.48)($0.66)$1.33 million$1.56 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Viveve Medical (NASDAQ:VIVE)
2017 EPS Consensus Estimate: ($1.96)
2018 EPS Consensus Estimate: ($1.17)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.56)($0.56)($0.56)
Q2 20172($0.62)($0.43)($0.53)
Q3 20172($0.44)($0.43)($0.44)
Q4 20172($0.46)($0.42)($0.44)
Q1 20181($0.39)($0.39)($0.39)
Q2 20181($0.30)($0.30)($0.30)
Q3 20181($0.25)($0.25)($0.25)
Q4 20181($0.23)($0.23)($0.23)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Viveve Medical (NASDAQ:VIVE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Viveve Medical (NASDAQ VIVE)

Insider Ownership Percentage: 35.10%
Institutional Ownership Percentage: 65.92%
Insider Trades by Quarter for Viveve Medical (NASDAQ:VIVE)
Institutional Ownership by Quarter for Viveve Medical (NASDAQ:VIVE)

Insider Trades by Quarter for Viveve Medical (NASDAQ VIVE)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/23/2017Scott DurbinCFOBuy5,000$5.25$26,250.00View SEC Filing  
3/17/2017James G AtkinsonDirectorBuy375,000$4.00$1,500,000.00View SEC Filing  
3/17/2017Patricia SchellerCEOBuy12,500$4.00$50,000.00View SEC Filing  
6/17/2016James G. AtkinsonInsiderBuy100,000$5.00$500,000.00View SEC Filing  
6/17/2016Patricia SchellerCEOBuy6,000$5.00$30,000.00View SEC Filing  
6/17/2016Scott DurbinCFOBuy1,500$5.00$7,500.00View SEC Filing  
6/17/2016Stonepine Capital Management,Major ShareholderBuy300,000$5.00$1,500,000.00View SEC Filing  
9/23/20145Am Partners Ii, LlcMajor ShareholderBuy5,215,664$0.53$2,764,301.92View SEC Filing  
9/23/2014Daniel JanneyDirectorBuy1,895,788$0.53$1,004,767.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Viveve Medical (NASDAQ VIVE)

Source:
DateHeadline
Viveve Medical (VIVE) Presents At 8th Annual Craig-Hallum Alpha Select Conference - SlideshowViveve Medical (VIVE) Presents At 8th Annual Craig-Hallum Alpha Select Conference - Slideshow
seekingalpha.com - November 18 at 10:04 AM
Viveve Medical, Inc. (VIVE) Receives Consensus Rating of "Buy" from BrokeragesViveve Medical, Inc. (VIVE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - November 16 at 9:54 PM
Viveve Medical, Inc. (VIVE) Research Coverage Started at MizuhoViveve Medical, Inc. (VIVE) Research Coverage Started at Mizuho
www.americanbankingnews.com - November 16 at 7:47 PM
ETFs with exposure to Viveve Medical, Inc. : November 10, 2017ETFs with exposure to Viveve Medical, Inc. : November 10, 2017
finance.yahoo.com - November 12 at 1:11 PM
Edited Transcript of VIVE earnings conference call or presentation 8-Nov-17 10:00pm GMTEdited Transcript of VIVE earnings conference call or presentation 8-Nov-17 10:00pm GMT
finance.yahoo.com - November 12 at 1:11 PM
Reviewing Derma Sciences (DSCI) and Viveve Medical (VIVE)Reviewing Derma Sciences (DSCI) and Viveve Medical (VIVE)
www.americanbankingnews.com - November 9 at 11:06 PM
Viveve Announces Third Quarter 2017 Financial ResultsViveve Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 9 at 9:32 AM
Viveve Medical, Inc. (VIVE) Issues  Earnings ResultsViveve Medical, Inc. (VIVE) Issues Earnings Results
www.americanbankingnews.com - November 8 at 9:10 PM
Comparing Viveve Medical (VIVE) and Its RivalsComparing Viveve Medical (VIVE) and Its Rivals
www.americanbankingnews.com - November 7 at 7:22 PM
Viveve to Present at November Investor ConferencesViveve to Present at November Investor Conferences
finance.yahoo.com - November 2 at 10:55 AM
Viveve Launches GENEVEVE(TM) by Viveve Treatment in CanadaViveve Launches GENEVEVE(TM) by Viveve Treatment in Canada
www.marketwatch.com - November 1 at 10:24 AM
Viveve Medical (VIVE) and The Competition Head-To-Head AnalysisViveve Medical (VIVE) and The Competition Head-To-Head Analysis
www.americanbankingnews.com - October 27 at 9:39 AM
Streetwise Reports Examines Biotech Company that Receives Device Approval in Five More Countries and Revenue Increases 122% YOYStreetwise Reports Examines Biotech Company that Receives Device Approval in Five More Countries and Revenue Increases 122% YOY
finance.yahoo.com - October 26 at 11:51 AM
Viveve Medical, Inc. (VIVE) Given a $11.00 Price Target at Cowen and CompanyViveve Medical, Inc. (VIVE) Given a $11.00 Price Target at Cowen and Company
www.americanbankingnews.com - October 24 at 3:32 PM
VIVE: Q3 Revenue Beats, Details Imply Strong Q4VIVE: Q3 Revenue Beats, Details Imply Strong Q4
finance.yahoo.com - October 24 at 12:06 PM
BRIEF-Viveve gets regulatory nod to market Viveve System in MexicoBRIEF-Viveve gets regulatory nod to market Viveve System in Mexico
www.reuters.com - October 18 at 10:18 AM
Viveve Releases Preliminary Third Quarter 2017 Financial ResultsViveve Releases Preliminary Third Quarter 2017 Financial Results
feeds.benzinga.com - October 18 at 8:55 AM
ETFs with exposure to Viveve Medical, Inc. : October 16, 2017ETFs with exposure to Viveve Medical, Inc. : October 16, 2017
finance.yahoo.com - October 17 at 8:50 AM
Viveve Announces Regulatory Approval for Viveve System in MexicoViveve Announces Regulatory Approval for Viveve System in Mexico
finance.yahoo.com - October 17 at 8:50 AM
 Analysts Anticipate Viveve Medical, Inc. (VIVE) Will Post Quarterly Sales of $3.63 Million Analysts Anticipate Viveve Medical, Inc. (VIVE) Will Post Quarterly Sales of $3.63 Million
www.americanbankingnews.com - October 15 at 3:56 AM
Head-To-Head Review: Viveve Medical (VIVE) vs. Its RivalsHead-To-Head Review: Viveve Medical (VIVE) vs. Its Rivals
www.americanbankingnews.com - October 13 at 8:26 AM
Viveve Medical, Inc. :VIVE-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017Viveve Medical, Inc. :VIVE-US: Earnings Analysis: Q2, 2017 By the Numbers : October 4, 2017
finance.yahoo.com - October 6 at 12:29 PM
ETFs with exposure to Viveve Medical, Inc. : October 5, 2017ETFs with exposure to Viveve Medical, Inc. : October 5, 2017
finance.yahoo.com - October 6 at 12:29 PM
Viveve to Present at the Ladenburg Thalmann 2017 Healthcare ConferenceViveve to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 19 at 9:22 AM
Viveve Medical (VIVE) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - SlideshowViveve Medical (VIVE) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 8:57 PM
BRIEF-Viveve announces additional regulatory approvals in Middle EastBRIEF-Viveve announces additional regulatory approvals in Middle East
www.reuters.com - September 12 at 11:50 AM
Viveve Announces Additional Regulatory Approvals in Middle EastViveve Announces Additional Regulatory Approvals in Middle East
finance.yahoo.com - September 12 at 11:50 AM
Earnings Review and Free Research Report: Medtronics Q1 Non-GAAP EPS Grew 9% Y-o-Y; Topped ExpectationsEarnings Review and Free Research Report: Medtronic's Q1 Non-GAAP EPS Grew 9% Y-o-Y; Topped Expectations
finance.yahoo.com - September 11 at 8:17 AM
Form 4 VIVEVE MEDICAL, INC. For: Sep 06 Filed by: Morris ArleneForm 4 VIVEVE MEDICAL, INC. For: Sep 06 Filed by: Morris Arlene
www.streetinsider.com - September 9 at 9:44 AM
Viveve Medical, Inc. (VIVE) Expected to Announce Quarterly Sales of $3.63 MillionViveve Medical, Inc. (VIVE) Expected to Announce Quarterly Sales of $3.63 Million
www.americanbankingnews.com - September 8 at 8:20 AM
Viveve to Present at the 19th Annual Rodman & Renshaw Global Investment ConferenceViveve to Present at the 19th Annual Rodman & Renshaw Global Investment Conference
finance.yahoo.com - September 6 at 9:53 AM
LeMaitre Vascular (LMAT) and Viveve Medical (VIVE) Head-To-Head AnalysisLeMaitre Vascular (LMAT) and Viveve Medical (VIVE) Head-To-Head Analysis
www.americanbankingnews.com - September 5 at 8:46 PM
Viveve Medical, Inc. (VIVE) Receives Average Recommendation of "Buy" from AnalystsViveve Medical, Inc. (VIVE) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 5 at 8:48 AM
Viveve Medical (VIVE) vs. Varian Medical Systems (VAR) Head-To-Head AnalysisViveve Medical (VIVE) vs. Varian Medical Systems (VAR) Head-To-Head Analysis
www.americanbankingnews.com - September 1 at 9:02 AM
Head to Head Comparison: ResMed (RMD) & Viveve Medical (VIVE)Head to Head Comparison: ResMed (RMD) & Viveve Medical (VIVE)
www.americanbankingnews.com - September 1 at 4:16 AM
Viveve Medical, Inc. (VIVE) CFO Buys $26,250.00 in StockViveve Medical, Inc. (VIVE) CFO Buys $26,250.00 in Stock
www.americanbankingnews.com - August 23 at 8:50 PM
VIVE: Anticipating IDE Approval, Utilization JumpsVIVE: Anticipating IDE Approval, Utilization Jumps
finance.yahoo.com - August 23 at 1:32 PM
Viveve Medical, Inc. (VIVE) PT Set at $11.00 by Cowen and CompanyViveve Medical, Inc. (VIVE) PT Set at $11.00 by Cowen and Company
www.americanbankingnews.com - August 20 at 7:32 PM
-$0.43 EPS Expected for Viveve Medical, Inc. (VIVE) This Quarter-$0.43 EPS Expected for Viveve Medical, Inc. (VIVE) This Quarter
www.americanbankingnews.com - August 18 at 8:10 PM
Viveve Medical, Inc. (NASDAQ:VIVE) Receives Average Rating of "Buy" from BrokeragesViveve Medical, Inc. (NASDAQ:VIVE) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 11 at 7:00 PM
Viveve Medicals (NASDAQ:VIVE) Buy Rating Reiterated at Maxim GroupViveve Medical's (NASDAQ:VIVE) Buy Rating Reiterated at Maxim Group
www.americanbankingnews.com - August 11 at 4:58 PM
Edited Transcript of VIVE earnings conference call or presentation 10-Aug-17 9:00pm GMTEdited Transcript of VIVE earnings conference call or presentation 10-Aug-17 9:00pm GMT
finance.yahoo.com - August 11 at 3:49 PM
BRIEF-Viveve Medical reports Q2 loss per share $0.54BRIEF-Viveve Medical reports Q2 loss per share $0.54
www.reuters.com - August 10 at 8:40 PM
Viveve Announces Second Quarter 2017 Financial Results and Strategic Partnership with InControl Medical, LLCViveve Announces Second Quarter 2017 Financial Results and Strategic Partnership with InControl Medical, LLC
finance.yahoo.com - August 10 at 8:40 PM
Streetwise Reports Examines How Loan Provides Driver for Growth for Medical Device FirmStreetwise Reports Examines How Loan Provides Driver for Growth for Medical Device Firm
finance.yahoo.com - August 9 at 8:55 AM
Viveve to Announce Second Quarter 2017 Financial HighlightsViveve to Announce Second Quarter 2017 Financial Highlights
finance.yahoo.com - August 4 at 9:42 AM
Viveve Medical, Inc. (NASDAQ:VIVE) Set to Announce Quarterly Earnings on WednesdayViveve Medical, Inc. (NASDAQ:VIVE) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:22 AM
-$0.34 Earnings Per Share Expected for Viveve Medical, Inc. (NASDAQ:VIVE) This Quarter-$0.34 Earnings Per Share Expected for Viveve Medical, Inc. (NASDAQ:VIVE) This Quarter
www.americanbankingnews.com - July 31 at 2:20 PM
ETFs with exposure to Viveve Medical, Inc. : July 13, 2017ETFs with exposure to Viveve Medical, Inc. : July 13, 2017
finance.yahoo.com - July 14 at 9:45 AM
$3.29 Million in Sales Expected for Viveve Medical, Inc. (VIVE) This Quarter$3.29 Million in Sales Expected for Viveve Medical, Inc. (VIVE) This Quarter
www.americanbankingnews.com - July 9 at 9:46 AM

Social Media

Financials

Chart

Viveve Medical (NASDAQ VIVE) Chart for Sunday, November, 19, 2017
Loading chart…

This page was last updated on 11/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.